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Reduced renal prepro-epidermal growth factor mRNA and decreased
EGF excretion in ARF. Levels of prepro epidermal growth factor (EGF)
mRNA in renal cortical tissue and urinary EGF excretion have been
determined during cisplatin and ischenua-induced acute renal failure in
the rat. Northern analysis of polyadenylated RNAs of kidney cortical
tissue showed diminished renal preproEGF mRNA in rats injected with
cisplatin (5 mg/kg). The decrease in preproEGF mRNA occurred as
early as 12 hours in the kidney and persisted for at least three days after
cisplatin injection. The submandibular gland, a major site of EGF
synthesis, contained normal levels of preproEGF mRNA. Transplatin,
a non-nephrotoxic isomer of cisplatin, did not reduce renal preproEGF
mRNA levels. Northern analysis of polyadenylated RNAs of kidney
cortical tissue 24 hours after a 50 minute period of renal pedicle
clamping also showed reduced preproEGF mRNA levels. By contrast,
cisplatin increased renal c-fos inRNA. Urinary EGF excretion was also
reduced after cisplatin and ischemia and the decrease in EGF excretion
correlated significantly with the degree of renal failure. The data show
that nephrotoxic and ischemic renal cell injury reduces preproEGF
mRNA and urinary EGF excretion. Reduced preproEGF mRNA and
diminished EGF excretion may be important in the functional and
regenerative responses to renal injury.
Acute renal failure arises from a still incompletely understood
interplay between cellular and hemodynamic events where
renal cell injury is accompanied by reduced glomerular filtration
and diminished water reabsorption. The mediators of these
phenomena are unknown. Recovery from acute renal failure
depends on the repair and replacement of injured and necrotic
tubular cells by cells that are actively dividing [1]. Although the
signals that initiate the process of repair are poorly understood,
tissue cells that move from normally low (G0) to high rates of
DNA synthesis (S) and mitosis usually involve the activation of
a group of genes, including the proto-oncogenes and growth
factor genes, that initiate and sustain cell growth [2]. The
specific genes involved in this process in the kidney are
unknown.
Urine contains high concentrations of epidermal growth
factor (EGF), a polypeptide of 53 amino acids (Mr 6045) with
wide biologic effects [31. The kidney expresses high levels of a
single 5.0 kb preproEGF mRNA beginning shortly after birth
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[4] and synthesizes the large molecular weight polypeptide,
preproEGF, predicted by the structure of the mRNA [5]. The
function of this polypeptide is unknown but its structure, its
expression as a membrane protein in monkey kidney cells
transfected with a plasmid expressing preproEGF cDNA, and
its homology to the LDL receptor, suggest a membrane span-
ning protein with possible receptor function [4]. In the mouse
preproEGF mRNA and EGF are both localized exclusively to
the thick ascending limb of the loop of Henle and the distal
convoluted tubule [5, 6], while in the rat one study has identified
EGF in the afferent arteriole [7]. Receptors for EGF are present
in glomeruli, proximal tubules, and collecting ducts [8—15].
EGF elicits several responses from kidney cells that possess
its receptor. It contracts glomerular mesangial cells and [8]
augments their AVP and Ca-mediated release of arachidonate
and subsequent prostaglandin production [9]. EGF rapidly
increases intracellular pH and Ca concentration of primary
cultures of proximal convoluted tubules, followed by a later
increase in the activity of the hexose-monophosphate shunt
[10]. In the microperfused rabbit collecting duct, EGF reduces
both vasopressin and cAMP-induced increases in hydraulic
conductivity [11], but only when added to the basolateral or
blood side of the tubule. If EGF produced by the kidney has
such effect in vivo, it would have to gain access to the
peritubular surface of these cells. Transepithelial movement of
EGF has been demonstrated in the liver [12] and small intestine
[13], and thus trancytosis of EGF might exist in the kidney as
well. DNA synthesis increases modestly in each of these cells
after the addition of EGF [10, 14—17]. In vivo, EGF lowers
glomerular filtration when infused intraarterially in the rat [8].
Although these observations suggest a possible renal para-
crine or autocrine function for EGF and preproEGF, no partic-
ular renal functional role has been ascribed to either in vivo,
nor has any renal disease been correlated with changes in
preproEGF mRNA or its products. The high levels of expres-
sion of the EGF gene in normal kidney and the functional and
proliferative effects of EGF in the kidney prompted us to
explore the possibility that changes in preproEGF mRNA levels
might be produced by renal cell injury. We therefore measured
preproEGF mRNA abundance in the kidney during experimen-
tal acute renal failure (ARF) induced by the nephrotoxin
cisplatin [18] as well as by total occlusion of the renal artery.
We also investigated whether the levels of mRNA of other
genes change during acute renal failure, including several genes
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that are thought to control the cell cycle, to determine the
specificity of any changes in preproEGF mRNA levels pro-
voked by renal injury.
Methods
Data were collected in 65 male Sprague-Dawley rats weighing
250 to 500 g.
Animal preparation
Nephrotoxic renal failure was induced by the intraperitoneal
injection of cisplatin 5 mg/kg body weight i.p. (1 mg/ml 0.9%
NaCI). Rats were also injected with the non-nephrotoxic trans-
isomer of cisplatin, transplatin, 5 mg/kg body weight. Control
animals received equal volumes of 0.9% NaC 1 alone. Ischemia
was induced in anesthetized animals (ketamine, 75 mg/kg) by
occluding both renal arteries for 50 minutes under sterile
conditions. In sham operated animals, anesthesia, manipulation
of the renal hila, and exposure of the peritoneal cavity for 50
minutes was performed as in the ischemia studies, but occlusion
of the renal arteries was omitted.
Rats were also studied in metal metabolic cages fitted with
fine-mesh screens. All animals were offered 20 g of food and 50
ml of tap water daily. One group of rats (N =5) was injected
with cisplatin, 5 mg/kg, i.p. and another group (N = 5) was
injected with an equal volume of saline. Other animals under-
went renal vascular occlusion (N 6) or sham operation (N =
6) as described above. The daily consumption of food and water
was adjusted so that equal quantities were consumed by each
group. Rats were weighed daily and the 24-hour urine volume
measured. A portion of the urine was frozen and stored at 4°C
for subsequent analysis of EGF concentration.
RNA blot analysis
Relative levels of mRNA was analyzed by Northern analysis.
Kidneys were removed from anesthetized animals at varying
time periods after cisplatin and vehicle injection and 24 hours
after renal ischemia or sham operation. Total cortical RNA was
isolated by the guanidinium thiocyanate procedure [19] after
intra-arterial perfusion of the kidney with cold 154 mi NaC 1,
50 mM Tris (pH 7.4), and separation of the renal cortex and
outer stripe of the outer medulla from the rest of the kidney
medulla. Poly(A) RNA was isolated by oligo(dT)-cellulose
(Type 3, Collaborative Research, Bedford, Massachusetts,
USA) chromatography [20]. Poly(A) RNA (5 pg/Iane) were
electophoresed through formaldehyde-l% agarose gels [21] and
transferred overnight to nitrocellulose membranes (BA 85,
Schleicher and Schuell, Inc., Keene, New Hampshire) as
described [22]. Hybridization was carried out with nick trans-
lated DNAs labeled with 32P-dCTP (500 Cilmmol) to a specific
activity of approximately 5 x 108 cpm/tg DNA [23]. Quantita-
tive variabilities of either isolation, application, or transfer of
RNAs were accounted for by reprobing the Northern blots with
a cDNA probe for beta-actin mRNA. Nitrocellulose blots were
prehybridized at 45°C overnight with denatured salmon sperm
DNA (0.1 mg/ml) in 5 x SSC, 50% deionized formamide, and
0.02% Denhardt's solution (0.02% ficoll, 0.02% polyvinylpyrro-
lidine, and 0.02% BSA), and hybridized at 45°C overnight in the
same solution containing 10% dextran sulfate and radiolabeled
probe. Non-specifically bound radioactivity was removed by
extensive washing at 60°C as described [24]. After washing, the
blots were air dried and exposed overnight to Kodak XAR film
(Eastman Kodak, Rochester, New York, USA) at —70°C with
intensifying screens. The cDNA probes for murine preproEGF
from plasmid pmegflO [25], and the human cytoplasmic beta
actin probe from plasmid pHFbetaA-3' UT-HF [26], were gifts
of G. I. Bell. The cDNA probes for c-fos and c-ras were
derived from plasmids pfos-1 [27] and HB-1 1 [28], respectively,
and were purchased from American Type Culture Collection
(Rockville, Maryland, USA). The cDNA for TGFbeta was a gift
from R. Derynck [29]. The plasmids were grown up in appro-
priate hosts and purified according to standard procedures. The
sequences used for nick translation were excised with appro-
priate restriction endonucleases and purified by preparative gel
electrophoresis. Isolation of the oncogene sequences from
agarose was accomplished by electroelution and ethanol pre-
cipitation in the presence of 2.5 M ammonium acetate.
Urinary EGF assay and blood urea determination
Urine samples were assayed in duplicate for EGF receptor-
binding activity using membranes from A43 1 cells as the source
of receptors and highly purified mouse EGF as '251-labeled
tracer and reference standard (Biomedical Technologies,
Stoughton, Massachusetts, USA). A standard curve using
known concentrations of unlabeled mEGF reference standard
was included in each assay. The sensitivity (10% displacement)
and half maximal displacement were 0.1 and 1.0 ng EGF/assay
tube, respectively. Normal rat urine contains no detectable
TGF alpha immunoreactivity [30], which can also bind to the
EGF receptor, and we did not detect TGF alpha mRNA in
kidneys of normal and cisplatin-treated animals (data not
shown). Blood urea nitrogen was measured on the first, fourth,
and seventh day after cisplatin injection, and one and seven
days after ischemia or sham operation using the diacetyl mon-
oxime method [31].
Results
Northern analysis of renal cortical mRNA from rats injected
with cisplatin showed reduced levels of preproEGF mRNA
(Fig. 1A). The decrease was apparent at 12 hours (Figs. 1, 2B)
and continued for as long as 72 hours following cisplatin
injection, the last period that such measurements were made
(Fig. 1). No change in the level of preproEGF mRNA was
evident in submandibular glands of cisplatin-injected rats (Fig.
2C), another major site of EGF production [5], or in kidneys of
rats injected with transplatin, a non-nephrotoxic isomer of
cisplatin (Fig. 2A). By contrast, cisplatin had entirely opposite
effects on levels of c-fos mRNA. c-fos transcripts increased
after cisplatin injection most conspicuously at 24 hours (Fig. 1).
Only a minor increase in the level of TGFbeta mRNA was noted
while no difference was observed in kidney levels of c-ras (Fig.
1), c-sis, or TGFalpha mRNAs after aS mg/kg dose of cisplatin
(data not shown).
To determine whether the changes in relative abundance of
preproEGF mRNA was restricted to cisplatin-induced acute
renal failure, we repeated these studies in rats undergoing
ischemia-induced renal failure. As in cisplatin-induced renal
failure, preproEGF mRNA was reduced 24 hours after a 50
minute period of total renal ischemia (Fig. 2A, compare lanes 4
and 5).
Hybridization intensity for beta-actin was either not different,
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Fig. 1. Northern analysis of renal preproEGF and proto-onco gene
mRNA levels at varying time points after cisplatin administration. Poly
(A) RNA samples (5 pg/lane) were isolated from male Sprague-
Dawley rat kidney cortex 12 hr (lane 1 and 2), 24 hr (lane 3 and 4), 36
hr (lanes 5 and 6), and 72 hr (lanes 7 and 8) after saline (negative control)
and cisplatin (5 mg/kg body wt) i.p., respectively. The identity of each
transcript is indicated on the right side of the figure. The scale on the left
is in kilobases (RNA ladder, BRL, Gaithersburg, Maryland, USA).
Except for preproEGF, only the region of hybridization with a given
probe is shown in the figure and the closest migrating marker is
indicated. All transcripts were detected on separate blots, which after
hybridization, washing and autoradiography, were boiled (5 mm) in
0.1% SDS, prehybridized, and hybridized with the beta-actin probe.
The results for the preproEGF and beta-actin blot are shown, while all
other transcripts are shown without the beta-actin probe. The level of
beta actin mRNA in each sample (lanes 1-8) was the same as that
shown. The same data was obtained when a newly prepared transfer
was hybridized with beta-actin alone (data not shown).
as in the case of cisplatin (Figs. 1, 2B) or increased, as in the
case of isehemia (Fig. 2A). Thus the reduced preproEGF
mRNA could not be accounted for by differences in the
isolation, application, or transfer of mRNA onto the blots.
The decline in renal preproEGF mRNA in cisplatin-induced
acute renal failure was associated with lower urinary EGF
excretion (Fig. 3A). Reduced EGF excretion preceeded the
increase in BUN and polyuria typical of cisplatin-induced renal
insufficiency (Fig. 3B). A marked fall in EGF excretion also
followed renal ischemia from 6853 148 (control) and 318 96
ng124 hours (ischemia) over the first 24 hours after renal artery
occlusion (P < 0.001). Moreover, BUN levels correlated with
the level of EGF excretion in individual rats after cisplatin
injection or isehemia (Fig. 4).
Fig. 2. Northern analysis of renal and submandibular gland
preproEGF mRNA during acute rena/failure in rats. A. Poly (A)RNA
samples (5 j.g/lane) were isolated from male Sprague-Dawley rat kidney
cortices, separated by gel electrophoresis, and hybridized with
preproEGF and beta-actin cDNA probes as described in the Methods.
For beta actin, only the region of hybridization with the probe is shown.
Kidneys were removed from anesthetized animals 24 hours after
intraperitoneal injection with transplatin 5 mg/kg body wt i.p. (lane 1),
0.9% NaCI (lane 2), cisplatin 5 mg/kg body wt (lane 3), 24 hours after
sham operation (lane 4), and 24 hours after 60 minutes of total renal
artery occlusion (lane 5). Labels are as indicated in Figure 1. B.
Northern analysis of renal cortical mRNA isolated from rats 12 hours
after injection with isotonic saline (lane 1) or cisplatin, 5 mg/kg body wt
i.p. (lane 2). C. Northern analysis of submandibular po1y(A) RNA of
rats injected with isotonic saline (lane I) or cisplatin, 5 mg/kg body wt
(lane 2) 24 hours before. Reprobing this blot for beta-actin mRNA
demonstrated equal hybridization intensity in both lanes (data not
shown).
Discussion
To our knowledge this is the first demonstration of an
association between reduced preproEGF mRNA, EGF excre-
tion and acute renal failure. The decrease was limited to the
kidney and transplatin, a non-nephrotoxic isomer of cisplatin,
did not reduce renal preproEGF (Fig. 2), indicating that the
reduction in preproEGF is related to renal cell injury rather
than to the presence of platinum itself. While cisplatin and
isehemia did not reduce all kidney mRNA and thus cannot
explain the fall in preproEGF mRNA (the Northern analysis of
beta-actin, Fig. 1, and c-fos, Figure 2), it is possible that renal
cell injury somehow inhibits total RNA synthesis specifically in
the cells that make preproEGF mRNA (vida infra).
The mechanism of the fall in preproEGF mRNA was not
1 2345678 A 2345
9.5—7.5—
7.5—
44— -'S — • •— preproEGF 44 • 0 —preproEGF
2.424
.1.4— 1.4—
—
24—- 2.44 4. —S —— fos
1.4—-
B 1 2 1 2
-It
9.5—1.4—0 S S S S 5— ras'
'0 MP7PO 414 — * — preproEGF
2.4— 2.4—
-S — - -— TGF
14
1.4—
2.4—
— — — S p-actin 2.4—
-p-actin
Safirstein et al: FGF in acute renal failure 813
0 1 2 3 4 5 6 7
Time, days after dsp/atm
Fig. 3. A. Daily urinary EGF excretion after cisplatin injection, Mean
values 1 SEM are shown. B. Association between blood urea nitrogen
(BUN), daily urine volume (Va), and daily EGF excretion (EEGF) in the
cisplatin-treated animals studied in A.
explored in these studies but it is of interest to note that the sites
of synthesis of preproEGF mRNA, the thick ascending limb of
Henle's loop and distal convoluted tubules, do not undergo
significant necrosis in cisplatin- [181, or ischemia-induced renal
failure [32]. Thus diminished preproEGF mRNA is not due to
the sloughing of cells producing preproEGF mRNA. Another
possibility is that cisplatin and ischemia reduce mRNA synthe-
sis by these segments generally. The capacity of the thick
ascending limb to maintain a steep transepithelial sodium gra-
EGF excretion, nglday
Fig. 4. Correlation (r) between daily EGF excretion and blood urea
nitrogen concentration (BUN) in rats injected with cisplatin (N = 3) or
undergoing ischemic renal failure (N = 5). Individual BUN and EGF
determinations were made on day 3 of cisplatin-induced renal failure
and on day 1 and 7 after renal ischemia. The solid line represents the
best fit of the data as determined by linear regression.
dient even during well established cisplatin-induced renal fail-
ure is not compromised [18], which would suggest that there is
no general defect in the metabolism of these cells after cisplatin.
By contrast, an hour of ischemia in the rat [33] and rabbit [34]
reduces the diluting capacity of Henle's loop shortly after
reflow. The medullary thick ascending limb of the isolated
perfused kidney has been shown to be particularly vulnerable to
anoxia [35], and the adenylate cyclase responsiveness of mem-
branes of the outer stripe of the outer medulla to AVP and NaF
remains low for up to eight days after a one hour period of
ischemia [361. These studies suggest that ischemia affects the
thick ascending limb more profoundly than cisplatin. Other
more specific transcriptional and post-transcriptional effects
(reduced mRNA stability) should be considered, but regardless
of the precise mechanism of reduced preproEGF mRNA during
cisplatin and ischemia-induced renal failure, our studies suggest
that in vivo the thick ascending limb may be more prominently
affected by these noxious stimuli than the gross morphologic
studies suggest.
The origin of urinary EGF has not been unequivocally
established, but several observations suggest that urinary EGF
is derived from its renal production. Unilateral nephrectomy
reduces EGF excretion by half and ablation of the submandib-
ular gland and duodenal Brunner's glands, other organs known
to produce EGF, do not reduce EGF excretion [7]. EGF lies
just outside the membrane-spanning domaine of the precursor
and could be released into the urine by the action of urinary
peptidases at arginine-asparagine at the amino-terminus and
arginine-histidine residues at the carboxy-terminus of the pre-
cursor [5]. Other urinary EGF peptides do exist and appear to
be cleavage products of EGF and the preproEGF precursor
[301. The most abundant species in human [37], mouse [38] and
rat [30] urine is the Mr 6045 peptide and all EGF-like peptides
are equipotent in the radioreceptor assay [38]. As both kid-
ney mRNA and urinary excretion fall while submandibular
preproEGF mRNA is unchanged by renal failure, our studies
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also suggest that urinary EGF reflects its renal production [7],
but the possibility exists that the decrease in urinary EGF
excretion may simply reflect decreased filtration of plasma
EGF.
The increase in c-fos mRNA (Fig. 1) preceeds the elevated
rates of DNA synthesis and new cell growth that develops in the
course of cisplatin-induced renal failure [39]. Other protoonco-
genes showed either minor increases (TGFbeta, Fig. 1), or no
change (c-ras, Fig. 1) suggesting that c-fos activation is rela-
tively specific. fos and other genes of an apparently coregulated
group of genes [40] are early participants in the initial response
to mitogenic stimuli [41—43]. Fos itself is a nuclear binding
protein that acts as a transacting transcriptional factor for other
genes, including those that participate in the growth response.
It is likely, then, that the increase in c-fos expression is part of
the initial cascade of genes that eventually leads to repair and
regeneration of the kidney after renal cell injury. Interestingly,
EGF is growth inhibitory in several cell types [44—46] and
retards the growth of kidney and liver when administered to
neonatal rats [47, 481. Thus, the reciprocal changes in c-fos and
preproEGF mRNA during acute renal failure may both be part
of the repair process in the kidney.
In summary, acute renal failure, whether induced by cisplatin
injection or renal artery occlusion, reduces renal preproEGF
mRNA levels and EGF excretion. EGF excretion correlates
significantly with impaired renal function during acute renal
failure. It remains to be determined whether reduced renal
preproEGF mRNA levels and EGF excretion are merely a
consequence of kidney damage or whether these reductions are
integral to the cascade of events that lead to renal failure or
participate in its repair.
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